3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Status
Completed
14
Recruiting
4
Unknown
3
Terminated
2
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
31
Lymphoma
18
Lymphoma, Large B-Cell, Diffuse
17
Sarcoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Neoplasm Metastasis
10
Hodgkin Disease
9
Lymphoma, Non-Hodgkin
8
Recurrence
7
Prostatic Neoplasms
7
Neoplasms
7
Multiple Myeloma
7
Burkitt Lymphoma
7
Ovarian Neoplasms
6
Leukemia
6
Lymphoma, B-Cell
5
Fallopian Tube Neoplasms
5
Cardiotoxicity
5
Carcinoma, Hepatocellular
5
Urinary Bladder Neoplasms
4
Osteosarcoma
4
Liver Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Lymphoma, Follicular
3
Leukemia, Myeloid, Acute
3
Leukemia, Biphenotypic, Acute
3
Colonic Neoplasms
3
Waldenstrom Macroglobulinemia
2
Interventions
Trabectedin
2
Doxorubicin
2
sodium thiosulfate
1
plitidepsin
1
milademetan
1
avelumab
1
atezolizumab
1
X-Rays
1
TTI-621
1
Specimen Handling
1
Reverse Transcriptase Polymerase Chain Reaction
1
Platinum
1
Nelfinavir
1
Magnetic Resonance Spectroscopy
1
Immunoenzyme Techniques
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gene Expression Profiling
1
Cytoreduction Surgical Procedures
1
Cyproheptadine
1
Cisplatin
1
Blotting, Western
1
Biopsy
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Liposarcoma
×
Doxorubicin
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts